NLX-112 (befiradol)
Levodopa-induced Dyskinesia in Parkinson's Disease
Key Facts
About Neurolixis
Neurolixis is a privately held, Paris-based biotech advancing a focused pipeline of first-in-class, highly selective serotonin 5-HT1A receptor agonists for CNS disorders. Its lead assets include NLX-112 (Phase 2 for Parkinson's disease dyskinesia), NLX-101 (Phase 1 for Rett and Fragile X syndromes), and NLX-204 (preclinical for depression/pain). The company is funded primarily through non-dilutive grants from prestigious foundations like The Michael J. Fox Foundation and the Rett Syndrome Research Trust, demonstrating strong validation of its scientific approach.
View full company profileAbout Neurolixis
Neurolixis is a privately held, Paris-based biotech advancing a focused pipeline of first-in-class, highly selective serotonin 5-HT1A receptor agonists for CNS disorders. Its lead assets include NLX-112 (Phase 2 for Parkinson's disease dyskinesia), NLX-101 (Phase 1 for Rett and Fragile X syndromes), and NLX-204 (preclinical for depression/pain). The company is funded primarily through non-dilutive grants from prestigious foundations like The Michael J. Fox Foundation and the Rett Syndrome Research Trust, demonstrating strong validation of its scientific approach.
View full company profile